US biotech company Advaxis (Nasdaq: ADXS) saw its shares surge 68% in premarket trading on Friday after the Food and Drug Administration lifted a clinical hold on the company's Phase I/II trial for an immuno-oncology drug combination.
The FDA has lifted the clinical hold on the company’s Investigational New Drug (IND) application for its Phase I/II study of axalimogene filolisbac (AXAL) in combination with durvalumab for the treatment of patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.
Advaxis stock ended the day with a 9.84% gain at $1.34.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze